Alembic Pharmaceuticals eyes 50% turnover from US market by 2020

Oncology oral solids unit inaugurated, with filings from site to commence in 6-12 months

The Vadodara-based Alembic Pharmaceuticals, which inaugurated its oncology oral solids facility in Panelav on Friday, is betting on the segment to drive its US sales in the medium term. As such, the company expects US sales to contribute to 50 per cent of its revenues by 2020.

At present, generic exports account for nearly 50 per cent of its turnover, which stood at Rs 2,985.91 crore in 2016-17. Pranav Amin, joint managing director, Alembic Pharmaceuticals said that by 2020 the contribution of exports, including active pharmaceutical ingredients or bulk drug exports, to its overall turnover would be around 60-65 per